Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Voyager Therapeutics Inc (NASDAQ: VYGR) was $3.30 for the day, down -8.33% from the previous closing price of $3.60. In other words, the price has decreased by -$8.33 from its previous closing price. On the day, 0.91 million shares were traded.
Ratios:
Our analysis of VYGR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 02 ’25 when Ferguson Toby sold 10,086 shares for $3.43 per share. The transaction valued at 34,595 led to the insider holds 157,914 shares of the business.
Sandrock Alfred sold 10,885 shares of VYGR for $37,336 on Apr 02 ’25. The President and CEO now owns 430,931 shares after completing the transaction at $3.43 per share. On Apr 02 ’25, another insider, Sandrock Alfred, who serves as the Officer of the company, bought 10,885 shares for $3.43 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.73 while its Price-to-Book (P/B) ratio in mrq is 0.67.
Stock Price History:
Over the past 52 weeks, VYGR has reached a high of $9.55, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is 1.32%, while the 200-Day Moving Average is calculated to be -34.75%.
Shares Statistics:
A total of 55.21M shares are outstanding, with a floating share count of 45.00M. Insiders hold about 18.69% of the company’s shares, while institutions hold 62.86% stake in the company.
Earnings Estimates
The performance of Voyager Therapeutics Inc (VYGR) in the stock market is under the watchful eye of 11.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.33 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$1.58 and -$2.95 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$1.63, with 11.0 analysts recommending between -$0.39 and -$2.99.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $20M to a low estimate of $1M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $29.58MFor the next quarter, 12 analysts are estimating revenue of $9.41M. There is a high estimate of $16.74M for the next quarter, whereas the lowest estimate is $1M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $63.75M, while the lowest revenue estimate was $9.47M, resulting in an average revenue estimate of $37.07M. In the same quarter a year ago, actual revenue was $80MBased on 11 analysts’ estimates, the company’s revenue will be $70.02M in the next fiscal year. The high estimate is $159.95M and the low estimate is $20M.
